The Finlay Institute is primarily responsible for the production of vaccines in Cuba, both for national application and for export.
Recently Mario Landis, responsible for the institution's control and quality, said on Radio Rebelde that the Cuban vaccine to protect children from pneumococcal infections will be ready for use by 2019.
This vaccine will be given to children between 1 and 5 years of age against diseases such as pneumonia, meningitis and infections of the bloodstream caused by this bacterium, diseases that cause childhood deaths.
The information was given during the IV International Congress of Research, Development and Innovation in the biopharmaceutical industry (IDIFARMA 2018), which took place from December 3 to 7 at the Havana Convention Center.
About 5000 children in selected centers in the provinces of Havana, Cienfuegos and Santiago de Cuba have already been vaccinated as part of clinical trials and it has been shown that the candidate vaccine is effective and that its reactions are similar to other types of vaccination. vaccines
"The application for registration will be filed by 2019. The pneumococcal vaccine will have a high impact because pneumococcus is
basically the bacterium that causes pneumonia and bacterial meningitis and in the current vaccination scheme does not exist because it has a high price in the external market and each child needs three, "said the expert.